Guggenheim Capital LLC reduced its position in shares of Perrigo (NYSE:PRGO) by 8.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 552,322 shares of the company’s stock after selling 52,431 shares during the period. Guggenheim Capital LLC owned approximately 0.39% of Perrigo worth $48,137,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Crossmark Global Holdings Inc. raised its holdings in Perrigo by 8.3% during the fourth quarter. Crossmark Global Holdings Inc. now owns 7,741 shares of the company’s stock worth $675,000 after purchasing an additional 595 shares in the last quarter. New Mexico Educational Retirement Board increased its holdings in Perrigo by 5.0% in the fourth quarter. New Mexico Educational Retirement Board now owns 12,700 shares of the company’s stock valued at $1,107,000 after buying an additional 600 shares in the last quarter. Norinchukin Bank The increased its holdings in Perrigo by 6.1% in the fourth quarter. Norinchukin Bank The now owns 10,472 shares of the company’s stock valued at $913,000 after buying an additional 601 shares in the last quarter. Brown Advisory Inc. increased its holdings in Perrigo by 10.9% in the third quarter. Brown Advisory Inc. now owns 6,245 shares of the company’s stock valued at $529,000 after buying an additional 613 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. increased its holdings in Perrigo by 4.3% in the third quarter. Nomura Asset Management Co. Ltd. now owns 18,350 shares of the company’s stock valued at $1,553,000 after buying an additional 749 shares in the last quarter. 79.11% of the stock is owned by hedge funds and other institutional investors.
In other news, CEO Uwe Roehrhoff bought 7,500 shares of the firm’s stock in a transaction that occurred on Monday, March 5th. The shares were purchased at an average price of $81.85 per share, for a total transaction of $613,875.00. Following the completion of the transaction, the chief executive officer now owns 4,900 shares in the company, valued at $401,065. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 6.90% of the stock is currently owned by company insiders.
A number of brokerages have issued reports on PRGO. Cantor Fitzgerald set a $107.00 target price on shares of Perrigo and gave the company a “buy” rating in a report on Friday, January 12th. Canaccord Genuity reaffirmed a “buy” rating and issued a $100.00 target price on shares of Perrigo in a report on Wednesday, January 17th. Berenberg Bank began coverage on shares of Perrigo in a report on Thursday, February 1st. They issued a “buy” rating and a $117.00 target price for the company. Finally, Leerink Swann began coverage on shares of Perrigo in a report on Tuesday, January 2nd. They issued a “market perform” rating and a $90.00 target price for the company. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $91.88.
Shares of PRGO traded down $1.73 during mid-day trading on Friday, reaching $81.99. 1,150,414 shares of the company’s stock were exchanged, compared to its average volume of 929,535. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.96 and a quick ratio of 1.40. Perrigo has a 52-week low of $63.68 and a 52-week high of $95.93. The stock has a market cap of $11,546.98, a price-to-earnings ratio of 16.63, a price-to-earnings-growth ratio of 2.03 and a beta of 0.76.
Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Thursday, March 1st. The company reported $1.28 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.25 by $0.03. Perrigo had a net margin of 2.42% and a return on equity of 11.54%. The business had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.26 billion. During the same period last year, the company posted $1.24 EPS. The company’s revenue was down 3.6% on a year-over-year basis. equities analysts expect that Perrigo will post 5.23 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, March 20th. Investors of record on Friday, March 2nd were given a dividend of $0.19 per share. The ex-dividend date was Thursday, March 1st. This represents a $0.76 dividend on an annualized basis and a yield of 0.93%. This is a positive change from Perrigo’s previous quarterly dividend of $0.16. Perrigo’s dividend payout ratio (DPR) is 15.42%.
ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/08/guggenheim-capital-llc-reduces-position-in-perrigo-company-plc-prgo.html.
Perrigo Company Profile
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.